InvestorsHub Logo
Followers 31
Posts 3757
Boards Moderated 0
Alias Born 01/29/2012

Re: greens12 post# 674

Saturday, 09/30/2017 6:01:45 PM

Saturday, September 30, 2017 6:01:45 PM

Post# of 1954
That's what I thought as well. By the way, I'm curious if we will get any new info at AASLD on Oct 20-24.

Significant improvements were also observed in other NASH-related genes of interest, including CYP7A1 (cholesterol metabolism), MAP3K5 (ASK1, oxidative stress), ANXA2 (inflammation), KRT18 (CK-18, cell apoptosis), ACTA2 (aSMA, fibrosis) and LGALS1 (Galectin 1, fibrosis). Detailed results from this study will be presented at the 68th annual meeting of the American Association for the Study of Liver Diseases (AASLD), October 20-24, 2017 in Washington, D.C.



https://aasld2014.uberflip.com/i/842331-2017lmbrochure/9?m4=

http://www.prnewswire.com/news-releases/viking-therapeutics-announces-results-of-gene-expression-analysis-from-in-vivo-study-of-vk2809-in-non-alcoholic-steatohepatitis-nash-300516852.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VKTX News